CP-020 Switching to dolutegravir in monotherapy

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Antiretroviral monotherapy presents several significant benefits, such as reduction of toxicity, and drug and cost saving, as well as preserving future options with other classes of antiretrovirals and improved adherence.

Purpose

To assess the effectiveness and safety of simplification to a monotherapy with dolutegravir (DTG) in experienced HIV patients and to evaluate the economic impact.

Material and methods

A retrospective observational study was carried out. We included all patients who presented in the last 48 weeks with viral load (VL) undetectable and CD4 cell count >250, and who switched to DTG as monotherapy in 2015. Demographic and clinical characteristics were recorded at weeks 0, 12 and 24: sex, age, VL, CD4 cell count, fasting lipid profile (low density lipoprotein (LDL)/high density lipoprotein (HDL), total cholesterol (TC), triglycerides (TG)) and glomerular filtration rate (GFR).

Material and methods

We evaluated the saving strategy by the average cost difference of previous treatments in comparison with monotherapy with DTG for 1 year.

Results

38 patients were included: 31 (82%) were men with a median age of 52 years. No patient failed or was switched for another reason. 19 (50%) patients are at <24 weeks in the study period. Only 1 (2.6%) patient had VL 45 copies/mL at week 12, but VL was undetectable at week 24.

Results

All values are expressed as median, unless otherwise indicated.

Results

Regarding previous treatments, patients were divided as follows: 14 (37%) patients were switched from 2 nucleoside reverse transcriptase inhibitors (NRTIs) + 1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), 13 (34%) patients from 2 NRTIs + 1 protease inhibitor (PI), 11 (29%) patients from 1 NNRTIs +1 integrase strand transfer inhibitors (INSTIs).

Conclusion

Switching to monotherapy with DTG proved safe (significantly improved lipid profile and GFR), effective (maintained levels of VL and CD4) and more economical. It is necessary to carry out more studies to corroborate this strategy.

Conclusion

No conflict of interest

Related Topics

    loading  Loading Related Articles